UroAlerts - Prostate Cancer Weekly

July 07, 2026

Videos

Peer-to-Peer Clinical Conversations

Rectal Spacers in Prostate Radiotherapy: Balancing Efficacy, Safety, and Patient Experience - Michael Greenberg & Daniel Welchons

Zachary Klaassen speaks with Michael Greenberg and Daniel Welchons about rectal spacing before prostate cancer radiotherapy.

View

Interim PSMAddition Analysis Shows Lutetium PSMA-617 Improves rPFS in mHSPC - Scott Tagawa

Scott Tagawa

Oliver Sartor speaks with Scott Tagawa about the PSMAAddition trial examining lutetium PSMA-617 added to androgen deprivation therapy and androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer.

View

Beyond the Abstracts

Emerging Evidence for Sequencing and Combining PSMA-Based Therapies in Prostate Cancer - Beyond the Abstract

The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer - Beyond the Abstract

Conference Coverage

SNMMI 2026: Baseline PSMA PET Tumor Volume Predicts Overall Survival with 177Lu-PSMA-I&T in Individual mCRPC patients: A Single-Center Real-World Study

SNMMI 2026: Longitudinal Outcomes of PSMA PET/CT-Detected Bone Oligometastases: A Two-Center Study

AUA 2026: Radiographic Progression-free Survival as a Meaningful Endpoint in Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TALAPRO-2 Randomized Clinical Trial

APCCC 2026: Prevention and Management of Radioligand Therapy Induced Xerostomia

APCCC 2026: Radiation Therapy of the Primary in Patients with mHSPC

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.

Comparison of MRI-guided in-bore and fusion biopsy for small PI-RADS 4 prostate lesions.

Racial Differences in Psychosocial Outcomes Among Prostate Cancer Survivors: Insights From the All of Us Research Program.

Artificial intelligence-enabled MRI surveillance of prostate cancer: integrating PRECISE v2, PI-QUAL, and longitudinal biomarkers-a narrative review.

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Preparation of electroplated zinc-68 targets for gallium-68 cyclotron production using recovered zinc-68.

Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity.

Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations.

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

Prostate cancer: Value of the PI-FAB score and volume-adjusted PSA density in recurrence assessment after HIFU.

Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.

Redefining robotic image-guidance - tomographic visualization of lesions during prostate cancer surgery via gantry-free robotic SPECT.

STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.

Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.

Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer - Beyond the Abstract

FDA Alignment to Advance ProstACT Global Phase 3 Trial

External validation of the European association of urology biochemical recurrence risk groups to predict mortality after radical prostatectomy or radiation therapy in a North American cohort.

Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.

Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.

Beyond the tumor: Recurrence-prone radiomics for prognostication in negative PSMA PET/CT scans of prostate cancer.

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

18F-Fluciclovine or 68Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial.

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Case of Basal Cell Prostate Cancer and Recurrence With Prostatic Adenocarcinoma in a United States Military Veteran Exposed to Agent Orange.

Topographical and stage-related expression of nectin-4 in prostate cancer.

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.

Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlerts - Prostate Cancer Weekly

Prostate Cancer

Login